Calamos Advisors
COGT icon

Calamos Advisors’s Cogent Biosciences COGT Stock Holding History

Calamos Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
+35,546
New +$1.24M ﹤0.01% 711

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Calamos Advisors's COGT Position: Q2 2026 in Review

Calamos Advisors opened a new position in Cogent Biosciences (COGT) in Q2 2026: 35,546 shares worth $1.38M. The stake represents ﹤0.01% of the portfolio and ranks #711 among its holdings.

322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Calamos Advisors held 35,546 shares of Cogent Biosciences worth $1.38M as of Q2 2026.
  • Cogent Biosciences was a new Calamos Advisors position in Q2 2026.
  • Cogent Biosciences made up ﹤0.01% of Calamos Advisors's portfolio in Q2 2026, its #711 holding.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.